The last year has seen a major shift in power at the top of
big pharma as patent losses and new blockbuster drugs shake up the old guard.
The Top Pharma List, based on data exclusively provided to
PME by consultancy group GlobalData, shows reveals Novartis is now number one
in terms of prescription medicine revenues for 2014, taking over from the
long-dominant Pfizer.
The Swiss firm has clearly made its diversification model
work as recent acquisitions, such as that of eye care company Alcon (which made
it the leading ophthalmology group in the world), and a strong pipeline of drugs
across multiple therapy areas, have mitigated major losses from the $6bn in anual
sales that once came from blood pressure pill Diovan (valsartan).
But despite being pushed into second place, Pfizer has
nevertheless managed a strong comeback after the punishing loss of patent
product for Lipitor (atorvastatin). The statin, which once brought in $13bn a
year, began losing patents in 2012 and its sales last year were just $2.8bn.
This is because Pfizer too has made changes, including the
sale of its animal health unit Zoetis and purchase of biosimilar firm Hospira,
as it looks to focus more heavily on new medicines, most notably in oncology, which
are bringing in strong and consistent sales for the firm.
Special mention should also be made to Gilead that has
jumped into the top ten pharma firm list (after being outside the top 20 for
its entire corporate life) and is now ranked the ninth biggest by sales.(Más)
Ver también:
Ver también:
Entradas
No hay comentarios:
Publicar un comentario